EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcome of an Accelerated Treatment Algorithm for Patients Developing Diarrhea as a Complication of Ipilimumab-Based Cancer Immunotherapy in a Community Practice

Clarice Ho, Wolfram Samlowski iD

Current Oncology · 2024

DOI: 10.3390/curroncol31060260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Clarice Ho und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Nevada, Reno, NV 89557, USA. Hauptthemen laut MEDLINE: Ipilimumab, Diarrhea, Immunotherapy. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, US National Institutes of Health, National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune-mediated diarrhea represents a serious complication of checkpoint inhibitor therapy, especially following ipilimumab-based treatment. Efficient diagnosis and control of diarrhea remains an ongoing challenge. We developed an accelerated management paradigm for patients with ipilimumab-induced diarrhea. Patients who developed significant diarrhea (>five loose stools/day) were presumed to be developing immune colitis. Therapy was interrupted and patients were treated with a methylprednisolone dose pack. If diarrhea was not completely resolved, high-dose steroids and infliximab were promptly added. Only non-responding patients underwent further evaluation for infection or other causes of diarrhea. A total of 242 patients were treated with ipilimumab-based regimens. Forty-six developed significant diarrhea (19%) and thirty-four (74.4%) had a rapid resolution of diarrhea following glucocorticosteroid and infliximab treatment. The median time to resolution of diarrhea was only 8.5 ± 16.4 days. Accelerated treatment for presumed immune-mediated diarrhea resulted in the rapid control of symptoms in the majority of patients. There were no intestinal complications or deaths. Immunosuppressive therapy for diarrhea did not appear to decrease the remission rate or survival. After the control of diarrhea, most patients were able to continue their planned immunotherapy. Further testing in 11/46 patients with unresponsive diarrhea revealed additional diagnoses, allowing their treatment to be adjusted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IpilimumabDiarrheaImmunotherapyHumansMaleFemaleMiddle AgedAgedAlgorithmsNeoplasmsAdultTreatment Outcome

Stichwörter der Autor:innen

checkpoint inhibitorsdiarrheaglucocorticosteroidsinflammatory colitisinfliximabipilimumabnivolumab

Substanzen

Ipilimumab

Autor:innen und Institutionen

  • School of Medicine, University of Nevada, Reno, NV 89557, USA.
  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89148, USA.
  • Kerkorian School of Medicine, University of Nevada Las Vegas (UNLV), Las Vegas, NV 89106, USA.

ORCID-Profile: Wolfram Samlowski

Förderung

  • NCI NIH HHS
  • US National Institutes of Health
  • National Institutes of Health (NIH)

Zitieren

APA

Ho, C., & Samlowski, W. (2024). Outcome of an Accelerated Treatment Algorithm for Patients Developing Diarrhea as a Complication of Ipilimumab-Based Cancer Immunotherapy in a Community Practice. Current Oncology. https://doi.org/10.3390/curroncol31060260

Vancouver

Ho C, Samlowski W. Outcome of an Accelerated Treatment Algorithm for Patients Developing Diarrhea as a Complication of Ipilimumab-Based Cancer Immunotherapy in a Community Practice. Current Oncology. 2024. doi:10.3390/curroncol31060260

BibTeX
@article{Ho2024,
  author = {Ho, Clarice and Samlowski, Wolfram},
  title = {Outcome of an Accelerated Treatment Algorithm for Patients Developing Diarrhea as a Complication of Ipilimumab-Based Cancer Immunotherapy in a Community Practice},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31060260}
}
Kostenlos starten →